NINDS requests applications for clinical trial planning grants for type 1 diabetes. This announcement is made together with 3 other NIH components.
Type 1 diabetes is a serious chronic illness. New types of insulin, along with improved management and monitoring technologies, have the potential to improve outcomes. However, diabetes management requires complex balancing of medication dosing, diet, and exercise. This announcement supports the development of clinical trials in individuals with type 1 diabetes to improve glycemic control and/or to treat or reduce diabetes complications including peripheral neuropathy and stroke.
Letters of Intent Due February 16, 2012
Applications Due March 15, 2012
Potential applicants should contact Dr. Katrina Gwinn, program director, Neurogenetics Cluster, NINDS, at 301-496-5745 or email@example.com. For more information visit http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-11-010.html.